Global Market Direct’s pharmaceuticals report, “Biolink Group AS - Product Pipeline Review - 2013” provides data on the Biolink Group AS’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biolink Group AS’s corporate website, SEC filings, investor presentations and featured press releases, both from Biolink Group AS and industry-specific third party sources, put together by Global Markets Direct’s team.
- Biolink Group AS - Brief Biolink Group AS overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Biolink Group AS human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Biolink Group AS with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Biolink Group AS’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Biolink Group AS’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Biolink Group AS in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Biolink Group AS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Biolink Group AS. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Biolink Group AS and identify potential opportunities in those areas.
Table Of Contents
Biolink Group AS - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Biolink Group AS Snapshot 4 Biolink Group AS Overview 4 Key Information 4 Key Facts 4 Biolink Group AS - Research and Development Overview 5 Key Therapeutic Areas 5 Biolink Group AS - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Biolink Group AS - Pipeline Products Glance 9 Biolink Group AS Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 Biolink Group AS - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Biolink Group AS - Drug Profiles 11 CAN-C/D-3G 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 CIF-C/D-3G 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 HPT-C/D-3G 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Biolink Group AS - Pipeline Analysis 14 Biolink Group AS - Pipeline Products by Therapeutic Class 14 Biolink Group AS - Pipeline Products By Target 15 Biolink Group AS - Pipeline Products by Route of Administration 16 Biolink Group AS - Pipeline Products By Mechanism of Action 17 Biolink Group AS - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables
Biolink Group AS, Key Information 4 Biolink Group AS, Key Facts 4 Biolink Group AS - Pipeline by Indication, 2013 6 Biolink Group AS - Pipeline by Stage of Development, 2013 7 Biolink Group AS - Monotherapy Products in Pipeline, 2013 8 Biolink Group AS - Phase I, 2013 9 Biolink Group AS - Preclinical, 2013 10 Biolink Group AS - Pipeline By Therapeutic Class, 2013 14 Biolink Group AS - Pipeline By Target, 2013 15 Biolink Group AS - Pipeline By Route of Administration, 2013 16 Biolink Group AS - Pipeline Products By Mechanism of Action, 2013 17
List of Figures
Biolink Group AS - Pipeline by Indication, 2013 6 Biolink Group AS - Pipeline by Stage of Development, 2013 7 Biolink Group AS - Monotherapy Products in Pipeline, 2013 8 Biolink Group AS - Pipeline By Therapeutic Class, 2013 14